Last reviewed · How we verify

NCT05062902

A Novel Medical System for Quantitative Diagnosis and Personalized Precision Botulinum Neurotoxin Injection in Chronic Pelvic Pain Management

Not yet recruiting EARLY_PHASE1 Last updated 19 August 2025
What this trial tests

EARLY_PHASE1 trial testing High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device in Interstitial Cystitis in 46 participants. Not yet recruiting.

Timeline
15 September 2025
Primary endpoint
15 August 2027
1 December 2027

Quick facts

Lead sponsorHillMed Inc.
PhaseEARLY_PHASE1
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment46
Start date15 September 2025
Primary completion15 August 2027
Estimated completion1 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

HillMed Inc.

Who can join

Adults 18 to 60, female only, with Interstitial Cystitis or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate if it is possible to use intravaginal high-density surface electromyography to guide Botulinum neurotoxin (BoNT) injection to treat pelvic floor muscle overactivity that complicates Chronic Pelvic Pain (CPP).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of High Density Surface Electromyographic, precision botulinum neurotoxin injection guidance medical device

Trials testing the same drug.

Other recruiting trials for Interstitial Cystitis

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05062902.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing